Abstract:Antibiotic selection for the maintenance of expression plasmids is discouraged in the production of recombinant proteins for pharmaceutical or other human uses due to the risks of antibiotic residue contamination of the final products and the release of DNA encoding antibiotic resistance into the environment. We describe the construction of expression plasmids that are instead maintained by complementation of the lgt gene encoding a (pro)lipoprotein glyceryl transferase essential for the biosynthesis of bacterial lipoprotein. Mutations in lgt are lethal in Escherichia coli and other Gram-negative organisms. The lgt gene was deleted from E. coli and complemented by the Vibrio cholerae-derived gene provided in trans on a temperature-sensitive plasmid, allowing cells to grow at 30°C but not at 37°C. A temperature-insensitive expression vector carrying the V. cholerae-derived lgt gene was constructed, whereby transformants were selected by growth at 39°C. The vector was successfully used to express two recombinant proteins, one soluble and one forming insoluble inclusion bodies. Reciprocal construction was done by deleting the lgt gene from V. cholerae and complementing the lesion with the corresponding gene from E. coli The resulting strain was used to produce the secreted recombinant cholera toxin B subunit (CTB) protein, a component of licensed as well as newly developed oral cholera vaccines. Overall, the lgt system described here confers extreme stability on expression plasmids, and this strategy can be easily transferred to other Gram-negative species using the E. coli-derived lgt gene for complementation.IMPORTANCE Many recombinant proteins are produced in bacteria from genes carried on autonomously replicating DNA elements called plasmids. These plasmids are usually inherently unstable and rapidly lost. This can be prevented by using genes encoding antibiotic resistance. Plasmids are thus maintained by allowing only plasmid-containing cells to survive when the bacteria are grown in medium supplemented with antibiotics. In the described antibiotic-free system for the production of recombinant proteins, an essential gene is deleted from the bacterial chromosome and instead provided on a plasmid. The loss of the plasmid becomes lethal for the bacteria. Such plasmids can be used for the expression of recombinant proteins. This broadly applicable system removes the need for antibiotics in recombinant protein production, thereby contributing to reducing the spread of genes encoding antibiotic resistance, reducing the release of antibiotics into the environment, and freeing the final products (often used in pharmaceuticals) from contamination with potentially harmful antibiotic residues.

Stabilized gene duplication enables long-term selection-free heterologous pathway expression

Enhancing Homologous Recombination Efficiency in Pichia Pastoris for Multiplex Genome Integration Using Short Homology Arms.

Combinatorial Pathway Optimization in Escherichia Coli by Directed Co‐evolution of Rate‐limiting Enzymes and Modular Pathway Engineering

Optimizing multicopy chromosomal integration for stable high-performing strains

Homology-dependent recombination of large synthetic pathways into E. coli genome via λ-Red and CRISPR/Cas9 dependent selection methodology

Heterologous erythromycin production across strain and plasmid construction

Multilevel Systematic Optimization To Achieve Efficient Integrated Expression of Escherichia coli

Engineering E. coli strains using antibiotic-resistance-gene-free plasmids

Dual-Plasmid Mini-Tn5 System to Stably Integrate Multicopy of Target Genes in Escherichia coli

Engineering of a Highly Efficient Escherichia Coli Strain for Mevalonate Fermentation Through Chromosomal Integration

Exploiting Polyploidy for Markerless and Plasmid-Free Genome Engineering in Cyanobacteria

Endogenous 2μ Plasmid Editing for Pathway Engineering in Saccharomyces cerevisiae

Engineering plasmid copy number heterogeneity for dynamic microbial adaptation

Chromosomal Evolution of Escherichia Coli for the Efficient Production of Lycopene.

Chromosomal Engineering of Escherichia Coli for Efficient Production of Coenzyme Q10

A Novel Nonantibiotic, lgt-Based Selection System for Stable Maintenance of Expression Vectors in Escherichia coli and Vibrio cholerae

Integration Site Library for Efficient Construction of Plasmid-Free Microbial Cell Factories in Escherichia coli

A rapid and reliable strategy for chromosomal integration of gene(s) with multiple copies

Engineering of Escherichia coli for Lycopene Production Through Promoter Engineering

Iterative Genome Editing of Escherichia Coli for 3-Hydroxypropionic Acid Production

Improved cryptic plasmids in probiotic Escherichia coli Nissle 1917 for antibiotic-free pathway engineering